This page has moved to here!
Vermont Cancer Center ~ 2013 Annual Report
Gary Stein, Ph.D., and Claire Verschraegen, M.D., Co-Directors
The commitments and operating principles of the Vermont Cancer Center emphasize eradicating cancer through transdisciplinary collaborative team approaches that engage scientists, physicians, physician investigators, behaviorists and health care professionals throughout the College of Medicine, the University, and Fletcher Allen Health Care.
Consistent with the translational cancer
research focus, the Vermont Cancer Center
embraces innovative basic, behavioral,
translational and clinical cancer research
and offers the most advanced clinical trials.
Further, the Vermont Cancer Center is dedicated
to maximizing opportunities for partnerships
between basic scientists, population health
scientists and physician investigators to link
tumor biology and behavior with the continuum
of early detection and treatment of cancer.
The VCC programs strategy focus on two primary issues in the control of tumors — studying the genesis of malignant cells, and the progression that leads to clinically significant disease. Pursuing mechanisms of malignancy is complemented by emphasis on cancer control and population health sciences. This approach enhances the capability of the Vermont Cancer Center to advance understanding of the processes and practices that encompass cancer prevention, early detection, therapy and survivorship.
Vermont Cancer Center core facilities and the clinical research office support initiatives ranging from genetic and epigenetic mechanisms to investigator-initiated clinical trials. Vermont Cancer Center (VCC) programs are exploring unique parameters of psychosocial and behavioral issues that are associated with cancer along with unique approaches to evaluating quality of care and assessing translational outcomes and health care economics with emphasis on developing a “roadmap for cancer prevention” with cancer screening and treatment to rural and underserved populations.
Translating advances in the biology and the pathology of cancer cells to enhance capabilities in cancer prevention, early detection, treatment and survivorship is through a seamless relationship of Vermont Cancer Center programs with ten transdisciplinary teams that are based on tumor types. The transdisciplinary teams optimize utilization of defined clinical pathways that incorporate clinical trials. The advanced capabilities of the transdisciplinary teams are reinforced by the Vermont Cancer Center clinical trials office, tissue bank and the “high functioning” translational cancer research laboratory.
The VCC is making significant contributions as a destination site through regional outreach, providing leadership in northern New England cancer center collaborations, engagement in service to the cancer research and clinical community and establishing global collaborations that broaden the impact of the Vermont Cancer Center research and clinical programs.
Last modified December 05 2016 11:23 AM